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INTRODUCTION
Adult smoking prevalence rates have leveled off within
the United States (Emmons et al. 1997). Studies suggest
that today’s US smoking population may largely repre-
sent individuals with co-morbid psychiatric problems
(Gilbert & Gilbert 1995). People with psychiatric illnesses
tend to smoke cigarettes at high rates with some, but not
all, co-morbid subgroups appearing more resistant to
contemporary smoking treatments compared with their
counterparts who lack such vulnerability (Hughes
1999). Treatment efforts have used patient-matching
approaches in which treatments were tailored to the pre-
senting psychiatric symptoms. Treatment programs tai-
lored to individuals prone to depression have been studied
with the greatest frequency (Hall et al. 1996; Hayford et
al. 1999; Hitsman et al. 1999). Few studies have exam-
ined whether modified smoking treatment approaches
promote abstinence for smokers with co-morbid schizo-
phrenia, a subgroup that reports unusually high rates of
smoking (Masterson & O’Shea 1984; Hughes et al. 1986)
and extreme difficulty stopping smoking (Lavin et al.
1996).
Approximately 1% of the US population has been
diagnosed with schizophrenia (American Psychiatric
Association 1994) and at least 70% of these individuals
smoke cigarettes (De Leon et al. 1995). Unfortunately,
efforts to promote long-term abstinence among patients
with schizophrenia is not well documented. Treatment
studies present evidence that few patients with schizo-
phrenia are able to obtain short-term smoking absti-
nence (Addington et al. 1997; Ziedonis & George 1997).
A number of these studies suggest that neurobiological
factors associated with schizophrenia interact with nico-
tine to reduce the likelihood of smoking abstinence
(Dalack et al. 1998). This paper explores whether patients
with schizophrenia need to change smoking behavior 
at a slower rate and require greater reinforcement for
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ABSTRACT
We evaluated literature that addresses the notion that flexible smok-
ing treatment approaches are warranted for smokers with a diagnosis of
schizophrenia. Understanding the biological and psychological mechanisms
that increase the likelihood of smoking and decrease the motivation to quit for
these individuals is addressed within the framework of a neurobiological 
model. We provide a brief overview of the limited smoking cessation treatment
literature for patients with schizophrenia and compare abstinence-focused
versus reduction-focused treatment modalities. The potential utility of the
reduction-focused approach to tobacco treatment for these smokers is evalu-
ated. Suggestions for future research to address the utility and efficacy of
reduction-focused interventions for smokers with schizophrenia are put forth.
We conclude with a consideration of the implications for the current under-
standing of smoking treatment among patients with co-morbid psychiatric
diagnoses.
KEYWORDS Harm reduction, nicotine dependence, schizophrenia.
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change in order to compensate for any abnormal neuro-
biological factors that may in fact exist to undermine 
quit attempts. Our review of the literature suggests 
that an alternative smoking treatment approach for
people with co-morbid schizophrenia may reflect a model
that builds skills and prompts abstinence once a lower
rate of smoking has been obtained and stabilized over
time.
The present paper will focus on research examining
excessive smoking within populations diagnosed with
schizophrenia. In conducting our review, we performed 
a computer search consisting of PsychLit (1971–2000)
and Medline (1966–2000) databases, using the search
terms ‘schizophrenia’ and ‘smoking’ to identify research
reports for this paper. We then selected papers from peer-
review journals or chapters written by prominent
researchers in the area of neurobiology, schizophrenia,
and/or cigarette smoking.
For the purposes of this paper, we restricted our
review to studies examining smokers diagnosed with
schizophrenia and/or schizoaffective disorder. The
Diagnostic and Statistical Manual of Mental Disorders, 4th
edition (DSM-IV) (American Psychiatric Association
1994) makes the differential diagnosis of schizoaffective
disorder from the diagnosis of schizophrenia in two
primary ways. Individuals who meet the criteria for
schizoaffective disorder have a diagnosable mood disor-
der (e.g. major depression) concurrent with symptoms
associated with the active phase of schizophrenia (e.g.
delusions, hallucinations, disorganized speech, grossly
disorganized or catatonic behavior and/or negative
symptoms). Delusions or hallucinations for at least
2 weeks in the absence of prominent mood symptoms
must also be present. No apparent differences exist in
smoking treatment approaches for individuals with these
psychotic subtypes, nor does it appear that such individ-
uals differ in their smoking behavior. Moreover, because
researchers who examine individuals with co-morbid
psychotic disorders and nicotine dependence typically do
not differentiate between schizophrenia and schizoaffec-
tive disorder, we will use the term ‘schizophrenia’ to
reflect individuals who carry the diagnosis of schizo-
phrenia or schizoaffective disorder.
TOBACCO USE DISORDER AND
SCHIZOPHRENIA: A
NEUROBIOLOGICAL MODEL
Two percent of the adult US smoking population re-
port suffering from schizophrenia (Hughes 1999). On
average, smokers diagnosed with schizophrenia smoke
more cigarettes per day and have longer smoking histo-
ries than smokers without current or past psychiatric ill-
nesses. After daily cigarette intake has been statistically
controlled, continine levels remain significantly higher
for smokers with schizophrenia compared with ones
without psychiatric illnesses (Onlincy et al. 1997).
Moreover, combined smoking treatments (behavioral and
pharmacological interventions) are relatively ineffective
in promoting long-term abstinence for smokers with
schizophrenia. The few published treatment trials, com-
bining intensive cognitive–behavioral therapy with nico-
tine replacement, produce modest 6-month abstinence
rates (12–17%) (Ziedonis & George 1997; Addington et
al. 1998; George et al. 2000).
Researchers have begun to explore the potential
mechanisms that explain the high co-morbidity between
nicotine dependence and schizophrenia (De Leon et al.
1995). Although patients with schizophrenia appear to
smoke for many of the same reasons as smokers who lack
psychiatric diagnoses (Glynn & Sussman 1990), other
evidence suggests that their psychiatric illness bolsters
the vulnerability to nicotine dependence. Among several
possible explanations (Dalack et al. 1998), the most
common assumption is that nicotine alleviates certain
psychiatric symptoms (Gilbert & Gilbert 1995; Ziedonis &
George 1997; Hughes 1999; Picciotto et al. 2000). For
example, smokers with schizophrenia may experience a
relief from negative symptoms, schizophrenia-related
cognitive dysfunction, and/or medication side-effects
(Dalack et al. 1998).
The assumption that patients with schizophrenia
smoke to alleviate their symptoms is supported by several
different, yet related, research findings. For example,
nicotine may serve to remedy the worsening of negative
symptoms caused by traditional antipsychotics, such as
haloperidol (Gerlach & Larsen 1999; Lyon 1999).
Researchers posit that the blockage of dopamine in the
mesocortical and mesolimbic pathways, presumably
caused by traditional antipsychotic medications, produce
blunted emotions and cognitive side-effects that mimic
negative symptoms (i.e. blunted affect, alogia, avolition
and anhedonia) (Barnes & McPhillips 1995; Lewander
1994). It is plausible that nicotine’s ability to enhance
dopaminergic functioning via cigarette smoking
(Benowitz et al. 1990), particularly along the blocked
pathways, may partially diminish negative symptoms
(Lyon 1999; Shimoda et al. 1999). It remains difficult to
differentiate whether nicotine reduces negative symp-
toms or neuroleptic-induced deficits that mimic such
symptoms. Nevertheless, the extent to which nicotine
relieves some of the chronically unpleasant symptoms
may help explain why patients with schizophrenia smoke
heavily. Ziedonis et al. (1994) support this premise with
their finding that patients who are regular smokers show
reduced negative symptoms in comparison to non-
smoking patients.
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Researchers also suggest that atypical antipsychotic
medications improve, rather than worsen, negative symp-
toms associated with schizophrenia (Llorca et al. 2000).
Presumably, this category of antipsychotic medication
influences negative symptoms along similar neurobiolog-
ical pathways as nicotine. To the extent that both nicotine
and atypicals improve negative symptom profiles, one
might expect that nicotine would bolster the therapeutic
properties of atypical medication (McEvoy et al. 1999) as
opposed to its therapeutic reduction of traditional
antipsychotic medication (McEvoy et al. 1991). Consistent
with this notion, smokers with schizophrenia compared
with their non-smoking psychiatric counterparts show
more enhanced therapeutic response to atypical antipsy-
chotics (McEvoy et al. 1999). Interestingly, when patients
are treated with atypicals, such as clozapine, their nega-
tive symptoms improve and they smoke significantly less
(George et al. 1995; McEvoy et al. 1995, 1999).
In addition, the influence of nicotine on the
dopamine-blocking effects of antipsychotic medications
may help buffer patients with schizophrenia from move-
ment disorders (e.g. dystonia, tremors, rigidity and aki-
nesia/bradykinesia). Certain antipsychotic medications,
especially the traditional agents, contribute to movement
disorders by blocking dopamine along the nigrostriatal
pathway (Casey 1993). Although yet to be directly tested,
nicotine’s ability to weaken the dopaminergic blocking
power of traditional antipsychotic medications may
lower the risk of movement disorders.
Other data that support the self-medication hypothe-
sis of nicotine dependence and schizophrenia include
nicotine’s effects on nicotinic acetylcholine receptors.
Nicotinic acteylcholine receptors are implicated in the
pathophysiology of schizophrenia (Dalack et al. 1998).
Specifically, a dysfunction in acetylcholine may be
responsible for signs and symptoms associated with
abnormal sensory gating, such as decreased attention,
difficulty with concentration and poor memory (Adler et
al. 1992, 1993). Some postulate that nicotine’s ability to
improve acetylcholine functioning reflects subsequent
improvement in auditory sensory gating deficits (Griffith
et al. 1998). Thus, nicotine’s alleviating effects on
sensory gating deficits may enable patients with psy-
chotic spectrum disorders to increase attention, concen-
tration, and perhaps memory by filtering out irrelevant
stimuli (Adler et al. 1992, 1993; Levin et al. 1996).
In general, neurobiological correlates linked to the
proposed self-medication hypothesis represent both
direct and indirect effects of nicotine, a nicotinic cholin-
ergic agonist, on numerous neurotransmitters, including
acetylcholine, dopamine and glutamate (Balfour 1989;
Carmody 1992). As represented in the schematic below
(Fig. 1), the proposed neurobiologically primed self-
medicating behavior might be selectively reinforced by
reductions in various undesirable characteristics associ-
ated with schizophrenia and its subsequent treatment.
BARRIERS TO QUITTING FOR SMOKERS
WITH SCHIZOPHRENIA
Patients with schizophrenia face numerous barriers that
may undermine their attempts to quit smoking. For
example, it is unclear whether they possess adequate
motivation to achieve a smoke-free lifestyle. Nicotine’s
ability to alleviate aversive psychiatric symptoms may
reinforce increased cigarette smoking for such patients.
Furthermore, patients with schizophrenia may have few
alternative reinforcers that are as effective as cigarettes in
reducing adverse psychiatric symptoms and in providing
a reliable source of pleasure (Eastwood 1993). Indeed,
this patient population may be less motivated to discon-
tinue a behavior so strongly associated with symptom
alleviation and reward. At present, there are inconsistent
results that show that patients with schizophrenia
possess adequate motivation to quit smoking (Addington
et al. 1997, 1998; Ziedonis & George 1997; Ziedonis &
Trudeau 1997; Addington 1998).
It is also unclear whether patients with schizophrenia
have access to the necessary supportive environment (i.e.
Schizophrenia Tobacco use
Negative symptoms
Anhedonia
Apathy
Blunted affect
Emotional withdrawal
Cognitive deficits
Auditory sensory gating
Physiological effects of nicotine (BF)
Increases pleasure and reduces
boredom
Increases emotional sensitivity and
enhances active coping
Normalizes attentional processes (e.g.
auditory sensory gating)
Tobacco
dependence
Barriers to quitting smoking (BF)
Severe nicotine withdrawal
Increases in negative symptoms
decreased attention and concentration
Lack of alternative reinforcers
for abstinence
Cognitive limitations to learning
self-management skills
Positive reinforcement from treatment
providers for continued smoking
Figure 1 The effects of a proposed self-medication model as it
applies to smokers with schizophrenia
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access to effective smoking cessation treatments and pos-
itive reinforcement from their mental health providers)
that helps to promote sustained abstinence. Despite evi-
dence to the contrary (Haller et al. 1996), many health-
care professionals express concerns that restricting
smoking among patients may substantially increase their
aggressive behaviors or exacerbate their psychotic symp-
toms. Health-care professionals within many psychiatric
institutions are therefore reluctant to enforce smoking
control actively and/or encourage smoking cessation
among such patients (Landow et al. 1995; Pearlman
1997).
Once patients with schizophrenia develop sufficient
motivation to quit within an environment that supports
abstinence-based efforts (Addington et al. 1997), the
issue becomes whether available smoking treatments
address their specific needs. Severe nicotine withdrawal
symptoms along with increases in mild psychiatric symp-
toms and medication side-effects, once buffered by
smoking, may encourage patients to resume smoking
(Dalack & Meador-Woodruff 1996). In particular,
patients who quit without adequate pharmacological
adjuncts and/or effective self-control strategies for man-
aging their symptoms may be at increased risk for relapse
to smoking. Unfortunately, even if these patients are
taught self-management skills, possible cognitive deficits
(Addington & Addington 1999) may undermine their
ability to acquire and access the skills important to 
successful quitting.
SMOKING CESSATION AND
SCHIZOPHRENIA
Although some researchers advocate specific guidelines
for treating smokers with co-morbid schizophrenia
(Docherty et al. 1996; Addington 1998), it has been his-
torically difficult to evaluate the efficacy of such pro-
grams. For instance, available treatment trials for
smokers with schizophrenia have methodological limita-
tions, including the heterogeneous nature of schizophre-
nia samples, small sample sizes, the lack of defined
interventions and the lack of control groups. In addition,
issues involving cognitive deficits (Addington &
Addington 1999), questionable motivation (Ziedonis &
Trudeau 1997) and the overall lower functioning
(Dickerson et al. 1999; Harvey et al. 2000) complicate the
design and development of smoking treatments targeting
these individuals. Such obstacles give rise to questions as
to whether individuals with schizophrenia benefit from
known smoking treatment modalities, most of which are
abstinence-based programs. Thus, the first step has been
to test the feasibility of employing standard smoking
treatment with these patients (see Table 1).
All studies report fair end of treatment retention 
rates of 50–94%. For the studies that were successful 
at prompting abstinence, results show a decline in 
abstinence rates from end of treatment (42–50%) to 6-
month follow-up (12–17%) (Ziedonis & George 1997;
Addington et al. 1998; George et al. 2000; Evins et al.
Table 1 Characteristics of smoking cessation studies for patients with psychotic disorders.
Study n Psychotic diagnoses Intervention(s) 6-month outcome
Ziedonis & George (1997) 24 Schizophrenia (63%) & 10-week program: 13%
schizoaffective disorder Group and/or individual
(37%) nicotine replacement therapy
(NRT), behavioral counseling,
motivational enhancement,
supportive therapy and
psychoeducation
Addington et al. (1998) 50 Schizophrenia & 7-week group treatment using the 12%
schizoaffective disorder American Lung Association (ALA):
protocol: role-playing, anxiety
reduction, positive reinforcement 
& NRT
George et al. (2000) 45 Schizophrenia & 7-week ALA versus10-week specialized ALA = 17.6%*
schizoaffective disorder schizophrenia program, which SS = 10.7%*
includes motivational enhancement,
and relapse prevention, psychoeducation,
social skills training (all participants 
received NRT)
Evins et al. (2001) 18 Schizophrenia 12-week bupropion versus placebo + (3-month only)
9-week CBT psychosocial treatment Smoking reduction
only, no abstinence
* p < 0.05. Outcome reports of smoking abstinence were verified with carbon monoxide or urinary cotinine in all studies.
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2001). Nicotine replacement therapies (NRT) and group
attendance were linked (although not statistically veri-
fied) to those smoke-free at the 6-month assessment
(Ziedonis & George 1997; Addington et al. 1998; George
et al. 2000; Evins et al. 2001). For example, most subjects
abstinent at 6 months received some type of NRT. In addi-
tion, there appeared to be a dose–response relationship
between abstinence rates and group attendance. Within
the Addington et al. study, people abstinent at 3 and 6
months attended all seven group sessions, those absti-
nent at the end of treatment attended 6.5 sessions and
those who relapsed attended, on average, 5.5 sessions.
It remains unclear whether individuals with schizo-
phrenia substantially benefit from abstinence-based
smoking treatment approaches. At best, combined phar-
macological (e.g. NRT) and psychosocial interventions
prompt 6-month abstinence for very few patients. In
addition, other studies that provided nicotine replace-
ment (Hartman et al. 1991; Dalack et al. 1998) and sus-
tained-release bupropion (Evins & Tisdale 1999) without
concurrent psychosocial treatment have only produced
reductions in smoking behavior and not abstinence.
Similarly, positive reinforcement techniques without con-
joint pharmacological treatments appear to be effective in
reducing short-term smoking rates, but not in prompting
complete abstinence from smoking (Roll et al. 1998).
Such poor abstinence rates implicate a need for future
research to continue to test new smoking treatments and
to consider examining the efficacy of alternative treat-
ment options, such as reduction-focused strategies.
REDUCTION-FOCUSED APPROACHES 
AND SMOKING BEHAVIOR
Aside from abstinence-focused treatment, other treat-
ment models have been developed to allow for continued
use, albeit substantially reduced usage (Marlatt 1999).
The idea driving such reduction-focused approaches is
that lowering daily exposure to tobacco toxicants may
equally lower the risk of physical illness in those who
have great difficulty quitting. Although reduction-
focused models are gaining in popularity, particularly in
cultures with large numbers of illicit drug users, the
application of reduction principles in tobacco treatment
remains extremely controversial.
Reduction-focused theorists advocate that certain
products and strategies be employed to lower the mor-
bidity and mortality risks associated with chronic expo-
sure to tobacco toxicants (Kozlowski & Herman 1984;
Kozlowski 1989; Russell 1990; Benowitz 1995; Hughes
1995; Baer et al. 1998). In particular, products such as
the nicotine inhaler have been examined for their poten-
tial to reduce tar and nicotine exposure (Kozlowski et al.
1996; Hurt et al. 2000). Behavioral strategies have also
been employed to target the reduction of smoking.
Restricting access to cigarettes by banning smoking in
work areas and modifying smoking behavior by positively
reinforcing low carbon monoxide levels are examples 
of behavioral strategies that promote smoking reduc-
tion (Baer et al. 1998). For the most part, previous
research shows the feasibility of reducing exposure to
tobacco toxicants through reduction-focused approaches
(Institution of Medicine 2001).
Some data suggest that the products that have poten-
tial for reducing smoking behavior/tobacco toxicants,
with few exceptions (Pickworth et al. 1998), show little
or no reduction in biomarkers that assess harm exposure
(Kozlowski et al. 1996; Hurt et al. 2000; Institution of
Medicine 2001). Researchers posit that people change
their behaviors to maximize the absorption of nicotine.
For instance, when smokers block cigarette filter vents 
of ultra-light cigarettes with their lips, their carbon
monoxide more than doubles (Kozlowski et al. 1996).
Alterations in smoking behavior were also witnessed
when comparing the effects of bans on smoking in the
work-place. Smokers outside banned/restricted work
areas had higher numbers of puffs per cigarette and fin-
ished their cigarettes 30.4% more quickly compared with
smokers in non-banned areas, such as social settings
(Chapman et al. 1997).
However, there is some evidence of a dose–response
relationship between nicotine absorption and US Federal
Trade Commission (FTC) tar and nicotine yields of ciga-
rettes (Byrd et al. 1998). In other words, people who nor-
mally smoke ultra-light cigarettes absorb significantly
less nicotine than ones who smoke cigarettes with high
tar and nicotine yields. Unfortunately, at least in the
short-term, when people change from a high-yield ciga-
rette to an ultra-light, they tend to modulate behavior to
increase the level of nicotine absorbed. Future research
should test (a) whether people are able to sustain/stabi-
lize smoking reduction for prolonged periods and (b) if so,
whether their initial tendency to compensate for lower
nicotine levels decreases across periods of sustained
reduction.
EMPIRICAL EVIDENCE SUPPORTING
SMOKING REDUCTION FOR PATIENTS
WITH SCHIZOPHRENIA
Research employing reduction-focused interventions has
shown promise at reducing smoking or exposure to
tobacco toxicants among those with schizophrenia
(Barmann et al. 1980; Dawley et al. 1989; Roll et al.
1998). Even though patients often modulate behavior to
increase nicotine absorption during short-term reduction
790 Dennis E. McChargue et al.
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trials, some evidence shows decreases in the biomarkers
associated with harm (e.g. lower carbon monoxide). For
the purposes of this paper, we provide this evidence to
show the potential use of reduction approaches for
smokers with schizophrenia. However, it is important to
note that studies of the effects of smoking reduction have
been limited to very short-term outcomes. There is a need
for trials to assess whether such outcome data may 
be maintained and, if maintained, whether long-term
smoking reduction might reduce harm exposure and/or
prompt abstinence at a later date.
There are three specific areas that may help reduce
smoking behavior as well as exposure to tobacco toxi-
cants in patients with schizophrenia. These are limiting
their access to cigarettes, providing nicotine replacement
and reinforcing lowered smoking rates. Some research
evaluates whether limiting access to cigarettes within
psychiatric settings is feasible because of the fear that
smoking restrictions might foster problematic behaviors
among the patient population. In particular, the effects of
restricting smoking to designated areas or prohibiting
smoking within psychiatric hospitals have been tested.
Although various researchers delineate possible negative
effects of this approach (Greeman & McClellan 1991;
Hughes 1993), less than 10% of smokers with psy-
chiatric illnesses have difficulty adjusting to these re-
strictions (Greeman & McClellan 1991). The ones that
have the most difficulty are typically restricted from
leaving the hospital environment during a smoking ban.
Designating a well-ventilated smoking room with
restricted hours may help to minimize the negative effects
from banning smoking in an inpatient setting.
Because of the potential benefits associated with
decreasing expired carbon monoxide and lowering respi-
ratory tract inflammation from NRT (Rennaurd et al.
1990), researchers have also tested the feasibility and
safety of smoking reduction through the use of NRT
(Dalack & Meador-Woodruff 1996). The first line of evi-
dence showed that patients with schizophrenia (n = 13)
smoked significantly fewer cigarettes during a 48-hour
assessment period while on NRT compared with a 48-
hour placebo assessment period (Hartman et al. 1991).
Dalack & Meador-Woodruff extended these findings by
showing that patients (n = 10) were able to decrease their
expired carbon monoxide levels 20% while being admin-
istered NRT (22 mg/24 hours) for 2 days. In addition,
continued smoking while wearing the active patch did
not result in negative sequelae. Both studies using NRT
show the potential of reducing smoking rates and carbon
monoxide levels among patients with schizophrenia.
Behavioral reinforcement strategies (e.g. positive rein-
forcement) have also been used to reduce smoking
among patients with schizophrenia. Barmann et al.
(1980) were one of the first groups to test the hypothesis
that smoking could be reduced within a day-treatment
program in a psychiatric outpatient clinic. Their study
utilized an ABAB design with treatment and baseline
periods lasting a week in duration. Staff members were
instructed to reinforce non-smoking behavior with
tokens at randomly selected, unannounced times during
treatment weeks. Reinforcement tokens were lapel
buttons with the printed phrase, ‘Thank you for not
smoking’. The results indicated a 65% reduction of
observed smoking behavior during treatment weeks.
Roll et al. (1998) assessed the utility of monetary rein-
forcement for smoking abstinence with nicotine-depen-
dent outpatients with schizophrenia. An ABA design was
implemented using a cumulative reinforcement schedule
(after an initial payment of $3.00, subsequent payments
accrued by $.50 with a maximum payment of $10.00)
for CO levels lower than 11 p.p.m. during the interven-
tion condition; subjects were assessed three times per day
for 1 week. The results demonstrated a significant reduc-
tion in smoking during the intervention week compared
with both baseline periods.
Tidey et al. (1999a, 1999b) conducted laboratory
studies of tobacco use with patients meeting DSM-IV cri-
teria for schizophrenia. In one study, six patients under-
went assessments in which smokers could earn tobacco
puffs or money. Patients with the diagnoses of schizo-
phrenia responded in a manner consistent with smokers
without mental illness. That is, the availability of mone-
tary reinforcement significantly decreased the amount of
smoking, especially as it became more difficult to earn
cigarettes. This study points to the need to develop
common reinforcement for the reduction of tobacco use.
The other study investigated whether the point at which
patients with schizophrenia stopped working for tobacco
puffs was affected by previous abstinence. Indeed,
patients worked longer when they had been deprived pre-
viously. As such, the patients stopped working for tobacco
puffs at a higher breaking point when they attempted
abstinence. These studies support continued, systematic
exploration of the behavioral pharmacology of tobacco
use in this patient population. Although the authors
argue that results from non-psychiatric patients are
similar, their results provide more evidence that positive
reinforcement reduces smoking behavior among patients
with schizophrenia.
As potential reduction techniques for smokers with
schizophrenia, limiting access to smoking, replacing
nicotine and modifying behavior may be useful in evalu-
ating the potential benefits of an agenda that is not ini-
tially orientated to abstinence. However, one concern of
researchers and care providers alike is that using reduc-
tion methods might produce a rebound to baseline rates
of smoking once the intervention is discontinued
(Hughes 2000). More research is needed to investigate
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this rebound potential. If there is a greater possibility for
rebounding to baseline rates of smoking, future research
should examine the use of reduction as a long-term inter-
vention. Given the high reinforcement value of nicotine
for patients with schizophrenia, prolonged reduction
interventions may assist in the adaptation and stabiliza-
tion of lower smoking rates.
CONCLUSIONS
In this paper, we attempt to address the state of knowl-
edge regarding the unique patterns of tobacco use
among patients with schizophrenia. We demonstrate
that there are many interesting, but as yet unanswered,
questions regarding the problem of nicotine dependence
in this population. As such, we propose the following 
recommendations for the potential direction of reduction
approaches for smokers with schizophrenia.
Consistent with recommendations delineated by
Hughes (Hughes 2000), future research directions could
(a) address the feasibility of long-term maintenance of
reduced smoking, (b) develop methods that combat com-
pensatory behaviors (e.g. changes in smoking topogra-
phy), (c) document the health benefits from smoking
reduction and (d) investigate positive or negative changes
in self-efficacy and motivation toward future abstinence
as it applies to smokers with schizophrenia. Other ques-
tions that could be addressed that are specific to smokers
with schizophrenia include (a) whether smoking reduc-
tion also reduces the need for higher dosages of psy-
chiatric medications, (b) whether prolonged reduction
exacerbates psychiatric symptoms and increases the likeli-
hood of recidivism and (c) whether there are individual
differences that differentiate those who would benefit from
reduction-focused versus abstinence-based treatments.
Lastly, although current research on smokers with schizo-
phrenia appears to implicate the need for reduction
approaches, this need has been based primarily on the low
rates of abstinence following abstinence-based treatment.
Further examination of abstinence-based treatments
using more rigorous methodology (e.g. larger samples,
adequate control groups, defined interventions) will
provide data that may be helpful in the development of
specific recommendations regarding patients who might
be more appropriately served by reduction-focused versus
abstinence-based treatments.
ACKNOWLEDGEMENTS
This study was supported in part by VA Merit Review
Entry Program grant and NIH grant 1 K08 DA00467 to
Dr McChargue. We would like to thank Lee Cohen,
Sherry Pagato, Jessica Werth, Darlene Alt and Kelly
Petrunic for their editorial and administrative assistance.
REFERENCES
Addington, J. (1998) Group treatment for smoking cessation
among persons with schizophrenia. Psychiatric Services, 49,
925–928.
Addington, J. & Addington, D. (1999) Neurocognitive and 
social functioning in schizophrenia. Schizophrenia Bulletin, 
25, 173–182.
Addington, J., Nady el-Guebaly, Addington, D. & Hodgins, D.
(1997) Readiness to stop smoking in schizophrenia. Canadian
Journal of Psychiatry, 42, 49–52.
Addington, J., Nady el-Guebaly, Campbell, W., Hodgins, D. C. &
Addington, D. (1998) Smoking cessation treatment for
patients with schizophrenia. American Journal of Psychiatry,
155, 974–976.
Adler, L. E., Hoffer, L. D., Griffith, J., Waldo, M. C. & Friedman, R.
(1992) Normalization by nicotine of deficient auditory
sensory gating in the relatives of schizophrenics. Biological
Psychiatry, 32, 607–616.
Adler, L. E., Hoffer, L. D., Wiser, A. & Freedman, R. (1993)
Normalization of auditory physiology by cigarette smoking 
in schizophrenic patients. American Journal of Psychiatry, 
150, 1856–1861.
American Psychiatric Association (1994) Diagnostic and
Statistical Manual of Mental Disorders, 4th edn. Washington,
DC: Author.
Baer, J. S. & Murch, H. B. (1998) Harm reduction, nicotine, and
smoking. In: G. A. Marlatt, ed. Harm Reduction: Pragmatic
Strategies for Managing High-Risk Behaviors. New York:
Guilford Press.
Balfour, D. J. (1989) Influence of nicotine on the release of
monoamines in the brain. Progress in Brain Research, 79,
165–172.
Barmann, B. C., Burnett, G. F., Malde, S. R. & Zinik, G. (1980)
Token reinforcement procedures for reduction of cigarette
smoking in a psychiatric outpatient clinic. Psychological
Reports, 47, 1245–1246.
Barnes, T. R. & Mcphillips, M. A. (1995) How to distinguish
between the neuroleptic-induced deficit syndrome, depression
and disease-related negative symptoms in schizophrenia.
International Clinical Psychopharmacology, 3, 115–121.
Benowitz, N. L. (1995) Medical implications. Tobacco Control: an
International Journal, 4, 44–48.
Benowitz, N. L., Porchet, H. & Jacob, P. (1990) Phar-
macokinetics, metabolism, and pharmacodynamics of nico-
tine. In: Wonnacott, S., Russell, M. A. H. & Stolerman, I. P.,
eds. Nicotine Psychopharmacology: Molecular, Cellular, and
Behavioral Aspects, pp. 112–157. Oxford: Oxford University
Press.
Byrd, G. D., Davis, R. A., Caldwell, W. S., Robinson, J. H. &
Debethizy, J. D. (1998) A further study of FTC yield and 
nicotine absorption in smokers. Psychopharmacology, 139,
291–299.
Carmody, T. P. (1992) Affect regulation, nicotine addiction, 
and smoking cessation. Journal of Psychoactive Drugs, 24,
111–122.
Casey, D. E. (1993) Serotonergic and dopaminergic aspects of
neuroleptic-induced extrapyramidal syndromes in nonhu-
man primates. Psychophramacology, 112, S55–S59.
792 Dennis E. McChargue et al.
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs Addiction, 97, 785–793
Chapman, S., Haddad, S. & Sindjusake, D. (1997) Do work-place
smoking bans cause smokers to smoke ‘harder’? Results from
a naturalistic observational study. Addiction, 92, 607–610.
Dalack, G. W., Healy, D. J. & Meador-Woodruff, J. H. (1998)
Nicotine dependence in schizophrenia: clinical phenomenon
and laboratory findings. American Journal of Psychiatry, 155,
1490–1501.
Dalack, G. W. & Meador-Woodruff, J. H. (1996) Smoking,
smoking withdrawal, and schizophrenia: case reports and a
review of the literature. Schizophrenia Research, 22, 133–141.
Dawley, H. H., Williams, J. L., Guidry, L. S. & Dawley, L. T. (1989)
Smoking control in a psychiatric setting. Hospital and
Community Psychiatry, 40, 1299–1301.
De Leon, J., Dadvand, M., Canuso, C., White, A. O., Stanilla, J. K.
& simpson, G. M. (1995) Schizophrenia and smoking: an 
epidemiological survey in a state hospital. American Journal 
of Psychiatry, 152, 453–455.
Dickerson, F., Boronow, J. J., Ringel, N. & Parente, F. (1999)
Social functioning and neurocognitive deficits in outpatients
with schizophrenia: a 2-year follow-up. Schizophrenia
Research, 37, 13–20.
Docherty, J. P., Marzuk, P. M. & Barchas, J. D. (1996) Nicotine
dependence: perspectives on a new guideline from APA.
American Journal of Psychiatry, 153, 1247–1248.
Eastwood, R. (1993) Weeding out (letter). Lancet, 341, 1316.
Emmons, K. M., Kawachi, I. & Barclay, G. (1997) Tobacco
control: a brief review of its history and prospects for the
future. Hematological Oncology Clinics of North America, 2,
177–195.
Evins, A. E., Mays, V. K., Rigotti, N. A., Tisdale, T., Cather, C.,
Schoenfeld, D. & Goff, D. C. (2001) A placebo controlled trial
of bupropion added to cognitive behavioral therapy. Nicotine
and Tobacco Research, 3, 397–403.
Evins, A. E. & Tisdale, T. (1999) Bupropion and smoking cessa-
tion. American Journal of Psychiatry, 156, 798–799.
George, T. P., Sernyak, M. J., Ziedonis, D. M. & Woods, S. W.
(1995) Effects of clozapine on smoking in chronic schizo-
phrenic outpatients. Journal of Clinical Psychiatry, 56,
344–346.
George, T. P., Ziedonis, D. M., Feingold, A., Pepper, W. T.,
Satterbury, C. A., Winkel, J., Rounsaville, B. J. & Koster, T. R.
(2000) Nicotine transdermal patch and atypical antipsychotic
medications for smoking cessation in schizophrenia. American
Journal of Psychiatry, 157, 1835–1842.
Gerlach, J. & Larsen, E. B. (1999) Subjective experience and
mental side-effects of antipsychotic treatment. Acta Psychiatry
Scandinavia, 395, 113–117.
Gilbert, D. G. & Gilbert, B. O. (1995) Personality, psychopathol-
ogy, and nicotine response as mediators of the genetics of
smoking. Behavior Genetics, 25, 133–147.
Glynn, S. H. & Sussman, S. (1990) Why patients smoke [letter].
Hospital Community Psychiatry, 41, 1027.
Greeman, M. & Mcclellan, T. A. (1991) Negative effects of a
smoking ban on an inpatient psychiatry service. Hospital and
Community Psychiatry, 42, 408–412.
Griffith, J. M., O’Neill, J. E., Petty, F., Garver, D., Young, D. &
Freedman, R. (1998) Nicotinic receptor desensitization and
sensory gating deficits in schizophrenia. Biological Psychiatry,
44, 98–106.
Hall, S. M., Sees, K. L., Munoz, R. F., Reus, V. I., Duncan, C.,
Humfleet, G. L. & Hartz, D. T. (1996) Mood management and
nicotine gum in smoking treatment: a therapeutic contact
and placebo-controlled study. Journal of Consulting and Clinical
Psychology, 64, 1003–1009.
Haller, E., McNiel, D. E. & Binder, R. L. (1996) Impact of a
smoking ban on a locked psychiatric unit. Journal of Clinical
Psychiatry, 57, 329–332.
Hartman, N., Leong, G. B., Glynn, S. M., Wilkins, J. N. & Jarvik,
M. E. (1991) Transdermal nicotine and smoking behavior in
psychiatric patients. American Journal of Psychiatry, 148,
374–375.
Harvey, P. D., Jacobsen, H., Mancini, d., Parrella, M., White, L.,
Haroutunian, V. & Davis, K. L. (2000) Clinical, cognitive and
functional characteristics of long-stay patients with schizo-
phrenia: a comparison of VA and state hospital patients.
Schizophrenia Research, 25, 3–9.
Hayford, K. E., Patten, C. A., Rummans, T. A., Schroeder, D. R.,
Offord, K. P., Croghn, I. T., Glover, E. G., Fachs, D. P. L. & Hurt,
R. D. (1999) Efficacy of buproprion for smoking cessation in
smokers with a former history of major depression or alco-
holism. British Journal of Psychiatry, 174, 173–178.
Hitsman, B., Pingitore, R., Spring, B., Mahableshwarkar, A.,
Mizes, J. S., Segraves, K. A., Kristeller, J. L. & Xu, W. (1999)
Antidepressant pharmacotherapy helps some cigarette
smokers more than others. Journal of Consulting and Clinical
Psychology, 67, 547–554.
Hughes, J. R. (1993) Possible effects of smoke-free inpatient
units on psychiatric diagnosis and treatment. Journal of
Clinical Psychiatry, 54, 109–114.
Hughes, J. R. (1995) Applying harm reduction to smoking.
Tobacco Control: an International Journal, 4, 33–38.
Hughes, J. R. (1999) Co-morbidity and smoking. Nicotine and
Tobacco Research, 1, S149–S152.
Hughes, J. R. (2000) Reduced smoking: an introduction and
review of the evidence. Addiction, 95, S3–S7.
Hughes, J. R., Hatsukami, D. K., Mitchell, J. E. & Dahlgren, L. A.
(1986) Prevalence of smoking among psychiatric outpa-
tients. American Journal of Psychiatry, 143, 993–997.
Hurt, R. D., Croghan, G. A., Wolter, T. D., Croghan, I. T., Offord,
K. P., Williams, G. M., Djordjevic, M. V., Richie, J. P. & Jeffrey,
A. M. (2000) Does smoking reduction result in reduction of
biomarkers associated with harm? A pilot study using a nico-
tine inhaler. Nicotine and Tobacco Research, 2, 327–336.
Institute of Medicine (2001) Clearing the Smoke: Assessing the
Science Base for Tobacco Harm Reduction. Washington DC:
National Academy Press.
Kozlowski, L. T. (1989) Reduction of tobacco health hazards in
continuing users: individual behavioral and public health
approaches. Journal of Substance Abuse, 1, 345–357.
Kozlowski, L. T. & Herman, C. P. (1984) The interaction of psy-
chosocial and biological determinants of tobacco use: more
on the boundary model. Journal of Applied Social Psychology,
14, 244–256.
Kozlowski, L. T., Sweeney, C. T. & Pillitteri, J. L. (1996) Blocking
cigarette filter vents with lips more than doubles carbon
monoxide intake from ultra-low tar cigarettes. Experimental
and Clinical Psychopharmacology, 4, 404–408.
Landow, L., Szetela, B. & Know, M. A. (1995) Reducing smoking
among psychiatric inpatients: a survey of psychiatrists.
American Journal of Public Health, 85, 1169.
Lavin, M. R., Siris, S. G. & Mason, S. E. (1996) What is the 
clinical importance of cigarette smoking in schizophrenia?
American Journal on Addictions, 5, 189–208.
Levin, E. D., Wilson, W., Rose, J. E. & Mcevoy, J. (1996)
Nicotine–haloperidol interactions and cognitive performance
in schizophrenics. Neuropsychopharmacology, 15, 429–436.
Lewander, T. (1994) Neuroleptics and the neuroleptic-induced
deficit syndrome. Acta Psychiatry Scandinavia, 380, 8–13.
Schizophrenia and smoking treatment 793
© 2002 Society for the Study of Addiction to Alcohol and Other Drugs Addiction, 97, 785–793
Llorca, P. M., Lancon, C., Farisse, J. & Scotto, J. C. (2000)
Clozapine and negative symptoms. An open study. Progress in
Neuropsychopharmacology, Biology, and Psychiatry, 24, 373–
384.
Lyon, E. R. (1999) A review of the effects of nicotine on schizo-
phrenia and antipsychotic medications. Psychiatric Services,
50, 1346–1350.
Marlatt, G. A. (1999) Harm Reduction: Pragmatic Strategies for
Managing High-Risk Behaviors. London: Guilford Press.
Masterson, E. & O’Shea, B. (1984) Smoking and malignancy 
in schizophrenia. British Journal of Psychiatry, 145, 429–
432.
McEvoy, J. P., Freudenreich, O., McGee, M., Vanderzwaag, C.,
Levin, E. & Rose, J. (1995) Clozapine decreases smoking in
patients with chronic schizophrenia. Biological Psychiatry, 37,
550–552.
McEvoy, J. P., Freudenreich, O. & Wilson, W. H. (1999) Smoking
and therapeutic response to clozapine in patients with schiz-
ophrenia. Biological Psychiatry, 46, 125–129.
McEvoy, J. P., Schooler, N. R. & Wilson, W. H. (1991) Predictors
of therapeutic response to haloperidol in acute schizophrenia.
Psychopharmacological Bulletin, 27, 97–101.
Onlincy, A., Young, D. A. & Freedman, R. (1997) Increased 
levels of the nicotine metabolite cotinine in schizophrenic
smokers compared to other smokers. Biological Psychiatry, 42,
1–5.
Pearlman, T. (1997) Impact of a smoking ban on a locked 
psychiatric unit. Journal of Clinical Psychiatry, 58, 179.
Picciotto, M. R., Caldarone, B. J., King, S. L. & Zachariou, V.
(2000) Nicotinic receptors in the brain: links between molec-
ular biology and behavior. Neuropsychopharmacology, 22,
451–465.
Pickworth, W. B., Fant, R. V., Nelson, R. A. & Henningfield, J. E.
(1998) Effects of cigarette smoking through a partially
occluded filter. Pharmacology Biochemistry and Behavior, 60,
817–821.
Rennaurd, S. I., Daughton, D., Fujita, J., Oehlerking, M. B.,
Dobson, J. R., Stahl, M. G., Robbins, R. A. & Thompson, A. B.
(1990) Short-term smoking reduction is associated with
reduction in measures of lower respiratory tract inflammation
in heavy smokers. European Respiratory Journal, 3, 752–759.
Roll, J. M., Higgins, S. T., Steingard, S. & Mcginley, M. (1998) Use
of monetary reinforcement to reduce the cigarette smoking of
persons with schizophrenia: a feasibility study. Experimental
and Clinical Psychopharmacology, 6, 157–161.
Russell, M. A. H. (1990) The nicotine addiction trap: a 40-year
sentence for four cigarettes. British Journal of Addiction, 85,
293–300.
Shimoda, K., Someya, T., Morita, S., Hirokane, G., Noguchi, T.,
Yokono, A., Shibasaki, M. & Takahashi, S. (1999) Lower
plasma levels of haloperidol in smoking than in nonsmoking
schizophrenic patients. Therapeutic Drug Monitoring, 21,
293–296.
Tidey, J. W., Higgins, S. T., Bickel, W. K. & Steingard, S. (1999a)
Effects of response requirement and the availability of an
alternative reinforcer on cigarette smoking by schizophrenics.
Psychopharmacology, 145, 52–60.
Tidey, J. W., O’Neill, S. C. & Higgins, S. T. (1999b) Effects of absti-
nence on cigarette smoking among outpatients with schizo-
phrenia. Experimental and Clinical Psychopharmacology, 7,
347–353.
Ziedonis, D. M. & George, T. P. (1997) Schizophrenia and nico-
tine use: report of a pilot smoking cessation program and
review of neurobiological and clinical issues. Schizophrenia
Bulletin, 23, 247–254.
Ziedonis, D. M., Kosten, T. R., Glazer, W. M. & Frances, R. J.
(1994) Nicotine dependence and schizophrenia. Hospital and
Community Psychiatry, 45, 204–206.
Ziedonis, D. M. & Trudeau, K. (1997) Motivation to quit using
substances among individuals with schizophrenia: implica-
tions for a motivation-based treatment model. Schizophrenia
Bulletin, 23, 229–238.
